Role of magnetic resonance spectroscopy in brain space occupying lesions for detection of malignancy and grading of malignant lesions
DOI:
https://doi.org/10.18203/2320-6012.ijrms20205309Keywords:
Choline levels/N acetyl aspartate level, Magnetic resonanceAbstract
Background: Magnetic resonance (MR) spectroscopy is a non-invasive technique that enables tissue characterization on a biochemical level using radio frequency signals emitted by the nuclei in the tissue. Primary aim is at determining the utility of MR spectroscopy to differentiate malignant from benign lesions and to assess its role in grading of gliomas as secondary objectives.
Methods: MR system with proton spectroscopic capability using standard head coils and quantum gradients used in a sample size of 50 patients with intracranial space occupying lesions in conventional MRI. The diagnostic accuracy of the spectroscopic data based on the Cho/Naa ratios was used to detect the malignant lesions and distinguish them from the benign lesions.
Results: The lesion characterization using the MR spectroscopic data in distinguishing malignant lesions from benign was statistically compared with the histopathological data using chi square tests proved to be significant with p value of less than 0.05. Grading of the malignant space occupying lesion with the available spectroscopic data was done with the corresponding histopathology that proved statistically not significant.
Conclusions: Statistical data proves utility of MR spectroscopic data in differentiating malignant occupying lesions from benign. Role of spectroscopic data in grading the malignant lesion to differentiate to low and high grade could not be determined statistically which may be attributed to low sample size in the secondary objective.
References
Ross B, Bluml S. Magnetic resonance spectroscopy of the human brain. Anat Rec. 2001;265:54–84.
Scheau C, Preda EM, Popa GA, Ghergus AE, Capsa RA, Lupescu IG. Magnetic Resonance Spectroscopy–a non-invasive method in evaluating focal and diffuse central nervous system disease. J Med Life. 2012 Dec 15;5(4):423.
Harada M, Tanouchi M, Miyoshi H, Nishitani H, Kannuki S. Brain abscess observed by localized proton magnetic resonance spectroscopy. Mag Res Imag. 1994;12(8):1269-74.
Ott D, Hennig J, Ernst TH. Human brain tumors: assessment with in vivo proton MR spectroscopy. Radiology. 1993;186(3):745-52.
Kugel H, Heindel W, Ernestus RI, Bunke J, Du Mesnil R, Friedmann G. Human brain tumors: spectral patterns detected with localized H-1 MR spectroscopy. Radiol. 1992;183(3):701-9.
Sutton LN, Wang Z, Gusnard D, Lange B, Perilongo G, Bogdan AR, et al. Proton magnetic resonance spectroscopy of pediatric brain tumors. Neurosurg. 1992;31(2):195-202.
Safriel Y, Pol-Rodriguez M, Novotny EJ, Rothman DL, Fulbright RK. Reference values for long echo time MR spectroscopy in healthy adults. Am J Neuroradiol. 2005;26(6):1439-45.
Majós C, Julià-Sapé M, Alonso J, Serrallonga M, Aguilera C, Acebes JJ, et al. Brain tumor classification by proton MR spectroscopy: comparison of diagnostic accuracy at short and long TE. Am J Neur. 2004;25(10):1696-704.
Bruhn H, Frahm J, Gyngell ML, Merboldt KD, Hänicke W, Sauter R, et al. Noninvasive differentiation of tumors with use of localized H-1 MR spectroscopy in vivo: initial experience in patients with cerebral tumors. Radiol. 1989;172(2):541-8.
Miller BL. A review of chemical issues in 1H NMR spectroscopy: N-acetyl-L-aspartate, creatine and choline. NMR Biomed. 1991; 4(2):47-52.
Adamson AJ, Rand SD, Prost RW, Kim TA, Schultz C, Haughton VM. Focal brain lesions: effect of single-voxel proton MR spectroscopic findings on treatment decisions. Radiol. 1998;209(1):73-8.
Howe FA, Barton SJ, Cudlip SA, Stubbs M, Saunders DE, Murphy M, Wilkins P, Opstad KS, Doyle VL, McLean MA, Bell BA. Metabolic profiles of human brain tumors using quantitative in vivo 1H magnetic resonance spectroscopy. Magnetic Resonance in Medicine: J Inter Soci Mag Res Med. 2003;49(2):223-32.
Taylor JS, Langston JW, Reddick WE, Kingsley PB, Ogg RJ, Pui MH, et al. Clinical value of proton magnetic resonance spectroscopy for differentiating recurrent or residual brain tumor from delayed cerebral necrosis. Inter J Rad Oncol Biol Phy. 1996;36(5):1251-61.
